Cargando…

Monoamine Levels and Parkinson’s Disease Progression: Evidence From a High-Performance Liquid Chromatography Study

Parkinson’s disease (PD) is associated with dysfunction of monoamine neurotransmitter systems. We investigated changes in the levels of monoamine and their metabolites in PD patients, together with their association to clinical profiles. PD patients and age-matched control subjects (n = 40 per group...

Descripción completa

Detalles Bibliográficos
Autores principales: Wichit, Patsorn, Thanprasertsuk, Sekh, Phokaewvarangkul, Onanong, Bhidayasiri, Roongroj, Bongsebandhu-phubhakdi, Saknan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8358115/
https://www.ncbi.nlm.nih.gov/pubmed/34393700
http://dx.doi.org/10.3389/fnins.2021.605887
_version_ 1783737269442576384
author Wichit, Patsorn
Thanprasertsuk, Sekh
Phokaewvarangkul, Onanong
Bhidayasiri, Roongroj
Bongsebandhu-phubhakdi, Saknan
author_facet Wichit, Patsorn
Thanprasertsuk, Sekh
Phokaewvarangkul, Onanong
Bhidayasiri, Roongroj
Bongsebandhu-phubhakdi, Saknan
author_sort Wichit, Patsorn
collection PubMed
description Parkinson’s disease (PD) is associated with dysfunction of monoamine neurotransmitter systems. We investigated changes in the levels of monoamine and their metabolites in PD patients, together with their association to clinical profiles. PD patients and age-matched control subjects (n = 40 per group) were enrolled. Using high-performance liquid chromatography (HPLC) with an electrochemical detector, levels of monoamines (dopamine, DA; norepinephrine, NE; epinephrine, EPI; and serotonin, 5-HT) were measured in plasma, while the metabolites (homovanillic acid, HVA; vanillylmandelic acid, VMA; and 5-hydroxyindoleacetic acid, 5-HIAA) were measured in urine. Plasma DA level was not significantly different between PD and control groups. PD patients had significantly higher plasma NE but lower EPI and 5-HT levels. PD patients had a significantly higher HVA/DA ratio and lower VMA/NE ratio than control subjects, while the 5-HIAA/5-HT ratio was not different between the groups. Regarding the association between monoamine levels and clinical profiles, the DA level had a negative relationship with disease duration and the 5-HT level had a negative relationship with severity of motor impairment. These findings emphasized the involvements of several neurotransmission systems and their association with clinical profiles in PD patients, demonstrated by quantification of monoamine levels in peripheral body fluids. This could benefit appropriate pharmacological treatment planning in respect of monoamine changes and might also help predict subsequent clinical symptoms.
format Online
Article
Text
id pubmed-8358115
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-83581152021-08-13 Monoamine Levels and Parkinson’s Disease Progression: Evidence From a High-Performance Liquid Chromatography Study Wichit, Patsorn Thanprasertsuk, Sekh Phokaewvarangkul, Onanong Bhidayasiri, Roongroj Bongsebandhu-phubhakdi, Saknan Front Neurosci Neuroscience Parkinson’s disease (PD) is associated with dysfunction of monoamine neurotransmitter systems. We investigated changes in the levels of monoamine and their metabolites in PD patients, together with their association to clinical profiles. PD patients and age-matched control subjects (n = 40 per group) were enrolled. Using high-performance liquid chromatography (HPLC) with an electrochemical detector, levels of monoamines (dopamine, DA; norepinephrine, NE; epinephrine, EPI; and serotonin, 5-HT) were measured in plasma, while the metabolites (homovanillic acid, HVA; vanillylmandelic acid, VMA; and 5-hydroxyindoleacetic acid, 5-HIAA) were measured in urine. Plasma DA level was not significantly different between PD and control groups. PD patients had significantly higher plasma NE but lower EPI and 5-HT levels. PD patients had a significantly higher HVA/DA ratio and lower VMA/NE ratio than control subjects, while the 5-HIAA/5-HT ratio was not different between the groups. Regarding the association between monoamine levels and clinical profiles, the DA level had a negative relationship with disease duration and the 5-HT level had a negative relationship with severity of motor impairment. These findings emphasized the involvements of several neurotransmission systems and their association with clinical profiles in PD patients, demonstrated by quantification of monoamine levels in peripheral body fluids. This could benefit appropriate pharmacological treatment planning in respect of monoamine changes and might also help predict subsequent clinical symptoms. Frontiers Media S.A. 2021-07-29 /pmc/articles/PMC8358115/ /pubmed/34393700 http://dx.doi.org/10.3389/fnins.2021.605887 Text en Copyright © 2021 Wichit, Thanprasertsuk, Phokaewvarangkul, Bhidayasiri and Bongsebandhu-phubhakdi. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neuroscience
Wichit, Patsorn
Thanprasertsuk, Sekh
Phokaewvarangkul, Onanong
Bhidayasiri, Roongroj
Bongsebandhu-phubhakdi, Saknan
Monoamine Levels and Parkinson’s Disease Progression: Evidence From a High-Performance Liquid Chromatography Study
title Monoamine Levels and Parkinson’s Disease Progression: Evidence From a High-Performance Liquid Chromatography Study
title_full Monoamine Levels and Parkinson’s Disease Progression: Evidence From a High-Performance Liquid Chromatography Study
title_fullStr Monoamine Levels and Parkinson’s Disease Progression: Evidence From a High-Performance Liquid Chromatography Study
title_full_unstemmed Monoamine Levels and Parkinson’s Disease Progression: Evidence From a High-Performance Liquid Chromatography Study
title_short Monoamine Levels and Parkinson’s Disease Progression: Evidence From a High-Performance Liquid Chromatography Study
title_sort monoamine levels and parkinson’s disease progression: evidence from a high-performance liquid chromatography study
topic Neuroscience
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8358115/
https://www.ncbi.nlm.nih.gov/pubmed/34393700
http://dx.doi.org/10.3389/fnins.2021.605887
work_keys_str_mv AT wichitpatsorn monoaminelevelsandparkinsonsdiseaseprogressionevidencefromahighperformanceliquidchromatographystudy
AT thanprasertsuksekh monoaminelevelsandparkinsonsdiseaseprogressionevidencefromahighperformanceliquidchromatographystudy
AT phokaewvarangkulonanong monoaminelevelsandparkinsonsdiseaseprogressionevidencefromahighperformanceliquidchromatographystudy
AT bhidayasiriroongroj monoaminelevelsandparkinsonsdiseaseprogressionevidencefromahighperformanceliquidchromatographystudy
AT bongsebandhuphubhakdisaknan monoaminelevelsandparkinsonsdiseaseprogressionevidencefromahighperformanceliquidchromatographystudy